Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 1/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.50 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.50 |
| ▸ | TSHR | P16473 | 3/20 | 0.41 |
| ▸ | TP53 | P04637 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 2/20 | 0.38 |
| ▸ | POLB | P06746 | 2/20 | 0.38 |
| ▸ | NPC1 | O15118 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.38 |
| ▸ | PBRM1 | Q86U86 | 1/20 | 0.38 |
| ▸ | KMO | O15229 | 1/20 | 0.38 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.37 |
| ▸ | SRD5A2 | P31213 | 1/20 | 0.36 |
| ▸ | HAVCR2 | Q8TDQ0 | 1/20 | 0.36 |
| ▸ | FABP3 | P05413 | 1/20 | 0.36 |
| ▸ | FABP4 | P15090 | 1/20 | 0.36 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.36 |
| ▸ | CA12 | O43570 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26132916 | 0.86 | DPP4 (0.54) | DPP4ALDH1A1KDM4EHSD17B10TSHR | |
| SCHEMBL7781012 | 0.83 | DPP4 (0.45) | DPP4ALDH1A1KDM4EHSD17B10TSHR | |
| SCHEMBL2127072 | 0.83 | DPP4 (0.45) | DPP4ALDH1A1KDM4EHSD17B10TSHR | |
| SCHEMBL17333135 | 0.83 | DPP4 (0.50) | DPP4ALDH1A1KDM4EHSD17B10TSHR | |
| SCHEMBL18688330 | 0.83 | DPP4 (0.50) | DPP4ALDH1A1KDM4EHSD17B10TSHR | |
| SCHEMBL950473 | 0.83 | KDM4E (0.53) | DPP4ALDH1A1KDM4EHSD17B10TSHR | |
| SCHEMBL7777986 | 0.83 | DPP4 (0.50) | DPP4ALDH1A1KDM4EHSD17B10TSHR | |
| SCHEMBL486824 | 0.82 | DPP4 (0.71) | DPP4ALDH1A1KDM4EHSD17B10TSHR | |
| SCHEMBL3457088 | 0.80 | DPP4 (0.47) | DPP4ALDH1A1KDM4EHSD17B10TSHR | |
| SCHEMBL16702731 | 0.79 | DPP4 (0.68) | DPP4ALDH1A1KDM4EHSD17B10TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 103 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-4161611-A | Process for the production of 2-methoxy-3,6-dichlorobenzoic acid | Veesicol Chemical Corporation (US) | 1979-07-17 | — | — | US | claimed |
| US-3931300-A | Process for the production of dichlorobenzoic acids | BASF AKTIENGESELLSCHAFT (DT) | 1976-01-06 | — | — | US | claimed |
| EP-3619205-B1 | INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION | VIIV HEALTHCARE UK NO 5 LTD (GB) | 2022-04-06 | — | — | EP | disclosed |
| CN-107827735-B | Synthetic method of 2-hydroxy-3, 6-dichlorobenzoic acid | 江苏联化科技有限公司 | 2021-07-30 | — | — | CN | disclosed |
| US-10954252-B1 | Inhibitors of human immunodeficiency virus replication | VIIV Healthcare UK (No.5) Limited (GB) | 2021-03-23 | — | — | US | disclosed |
| CN-105968000-B | A method of preparing dicamba | 四川福思达生物技术开发有限责任公司 | 2019-03-05 | — | — | CN | disclosed |
| CN-105859508-B | A kind of technique preparing dicamba | 四川福思达生物技术开发有限责任公司 | 2019-03-05 | — | — | CN | disclosed |
| CN-105859550-B | A kind of preparation process of dicamba | 四川福思达生物技术开发有限责任公司 | 2019-03-05 | — | — | CN | disclosed |
| CN-105884573-B | A kind of preparation method of dicamba | 四川福思达生物技术开发有限责任公司 | 2019-03-05 | — | — | CN | disclosed |
| US-20180298011-A1 | PYRAZOLO[1,5-A]PYRIMIDINES FOR ANTIVIRAL TREATMENT | GILEAD SCIENCES, INC. | 2018-10-18 | — | — | US | disclosed |
| US-9957275-B2 | Pyrazolo[1,5-A]pyrimidines for antiviral treatment | GILEAD SCIENCES, INC. (US) | 2018-05-01 | — | — | US | disclosed |
| US-5496816-A | Carbapenem antibacterial compounds, compositions containing such compounds and methods of treatment | MERCK & CO., INC. (US) | 1996-03-05 | — | — | US | disclosed |
| WO-1995025108-A1 | CARBAPENEM COMPOUNDS, COMPOSITIONS AND METHODS OF TREATMENT | MERCK & CO., INC. (US) | 1995-09-21 | — | — | WO | disclosed |
| US-RE31617-E | ANTICOAGULANTS; HYPOTENSIVE AND BRONCHODILATOR AGENTS | BRISTOL-MYERS COMPANY (US) | 1984-06-26 | — | — | US | disclosed |
| US-4161611-A | Process for the production of 2-methoxy-3,6-dichlorobenzoic acid | Veesicol Chemical Corporation (US) | 1979-07-17 | — | — | US | disclosed |
| US-4161611-A | Process for the production of 2-methoxy-3,6-dichlorobenzoic acid | Veesicol Chemical Corporation (US) | 1979-07-17 | — | — | US | disclosed |
| US-4154745-A | Isobenzofuran route to anthracycloquinones | RESEARCH CORPORATION (US) | 1979-05-15 | — | — | US | disclosed |
| US-4116981-A | 5,12-EPOXY-NAPHTHACENE-6,11-DIONE DERIVATIVES | Tsay, Yuh-Geng (TW) | 1978-09-26 | — | — | US | disclosed |
| US-3932407-A | BRONCHODILATORS, HYPOTENSIVE AGENTS, ANTICOAGULANTS | BRISTOL-MYERS COMPANY (US) | 1976-01-13 | — | — | US | disclosed |
| US-3931300-A | Process for the production of dichlorobenzoic acids | BASF AKTIENGESELLSCHAFT (DT) | 1976-01-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10954252-B1 | Inhibitors of human immunodeficiency virus replication | EIF2AK2, REV1, POLR2E | DPP4 3053/4885ALDH1A1 2628/4885KDM4E 1877/4885 |
| US-20180298011-A1 | PYRAZOLO[1,5-A]PYRIMIDINES FOR ANTIVIRAL TREATMENT | TYMP, ZC3HAV1, TYMS | DPP4 32/4885ALDH1A1 1823/4885KDM4E 2069/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.